CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 124 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 375 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02569996
NCT02569996Phase 3Completed
CompareCT.gov

A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen

Hoffmann-La Roche·interventional·Posted Oct 7, 2015·Updated Dec 10, 2015

In Brief

A Phase 3 clinical trial evaluating Rituximab for Lymphoma, Follicular. Completed, enrolled 124 participants across 21 sites.

Detailed Summary

This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma, Follicular
CountriesHungary
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 7, 2015
Enrollment StartJul 1, 2005
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8.1 yearsPosted 10.7 years ago

Interventions

Rituximabdrug

Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.